Author + information
- Johannes Schirmer,
- Volker Rudolph,
- Britta Goldmann,
- Lenard Conradi,
- Moritz Seiffert,
- Michael Schlueter,
- Edith Lubos,
- Hendrik Treede,
- Stefan Blankenberg,
- Hermann Reichenspurner and
- Stephan Baldus
Redo surgical mitral valve repair carries a high perioperative risk in the presence of severely reduced ventricular function and/or relevant comorbidities. We sought to assess the feasibility of catheter–based mitral valve repair using the MitraClip system in patients in whom previous surgical annuloplasty failed to maintain initial mitral regurgitation (MR) reduction.
Since starting the MitraClip program at our center in 9/2008, a total of 6 patients (age 75±12 years [range: 59–90 years]) with recurrence of symptomatic MR grade ≥3 following prior surgical mitral annuloplasty underwent MitraClip therapy. Time interval between mitral valve surgery and interventional procedure was 3.6±4.0 years (range: 0.8–9.0 years). Risk for redo surgery was considered high by means of logistic EuroScore II of 24.5±6.1 % and STS score of 18.7±8.3 %, respectively.
MitraClip implantation was successful in 4 of 6 patients. In these patients, procedure–related reduction in MR severity was three grades in one patient, two grades in two patients, and one grade in 1 patient. As a consequence, NYHA functional status improved from 4 to 2 in 2 patients and from 3 to 2 in the other 2 patients, respectively. One of the patients with failed MitraClip therapy underwent surgical valve repair. At 6–month follow–up, all 6 patients continued to be alive.
Mitral valve repair using the MitraClip system for recurrence of MR following prior surgical annuloplasty may represent a therapeutic option in a subgroup of symptomatic patients carrying a high–risk for redo surgery.
West, Room 2022
Sunday, March 10, 2013, 9:15 a.m.–9:25 a.m.
Session Title: Structural Heart Disease (Non–TAVR)
Abstract Category: 50. TCT@ACC–i2: Mitral ValveDisease
Presentation Number: 2906–11
- 2013 American College of Cardiology Foundation